ClinicalTrials.gg
RecruitingNCT07296211INSPIREUpdated Nov 13, 2026

INcreasing the Uptake of DSMES Program and Addressing Social Needs in Low-Income VulneRablE Immigrants

An interventional study of CHW-enabled CCL and Mobile health (mHealth) diabetes self-management education and support (DSMES) videos in Type2 Diabetes Mellitus, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 13, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Diabetes Mellitus by NYU Langone Health — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · NYU Langone Health.

Planned enrollment
6th of 21
480 · median 200
Started
2026
with 1 other
No phase
19 of 27
4 open now
Registered
26th of 27
by date

Among the 27 studies in Diabetes Mellitus by NYU Langone Health, this one is the 6th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 19 with no phase, and was the 26th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

4 of the 27 studies in Diabetes Mellitus by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Diabetes Mellitus by NYU Langone Health, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate a multi-level approach to improve diabetes control via access to social service supports and online, culturally-tailored diabetes self-management education and support (DSMES) videos among a community of primarily Chinese and Latino/a immigrants. The study aims to assess patient uptake, provider adoption, and INSPIRE program acceptability, appropriateness, feasibility, fidelity, penetration/reach, and maintenance.

Read the detailed description

In stage 1, the 8 family health center (FHC) clinics will be randomized 1:1 into Experimental Cohort A, which will receive the Community Health Worker (CHW)-enabled community-clinic linkage model (CCL) or Control Cohort B, with FHCs that will not receive the CHW-enabled CCL. Then, in stage 2, patients in clinics that received the CHW-enabled CCL will be randomized in a 1:1 ratio to Arm A who will receive text-based mhealth diabetes education videos or Arm B who will not receive mhealth.

03

Conditions studied

  • Type2 Diabetes Mellitus

Browse trials for

Keywords

  • T2DM
  • Diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, the patient participant must meet all the following criteria:

  1. ≥18 years old and ≤ 70 years old
  2. Self-identify their primary language as English, Mandarin, Cantonese, or Spanish
  3. Diagnosed with T2DM
  4. Has their most recent ≥8% or have a new diagnosis of T2DM within the past 6 months

For patient participants randomized to the mHealth cohort, they must meet the below inclusion criteria

1. Willing to receive text messages with brief videos regarding T2DM management

Exclusion criteria

Exclusion Criteria:

  1. Unable or unwilling to provide
  2. Unable to participate meaningfully in the intervention (e.g. uncorrected sight and hearing impairment)
  3. Is currently pregnant (Pregnant women will be excluded from this study because they may have special dietary restrictions that are not covered by our DSMES videos for the general population with T2DM.)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    Patients in a CHW-enabled clinic that receive mobile health (mHealth) videos

    For the first 6 months participants will receive CHW-enabled services from their clinic. Over the next 6 months participants will receive 24 culturally tailored diabetes education videos via text message.

    Behavioral: CHW-enabled CCL · Behavioral: Mobile health (mHealth) diabetes self-management education and support (DSMES) videos

  • Experimental
    Patients in a CHW-enabled clinic that do not receive mHealth videos

    For the first 6 months participants will receive CHW-enabled services from their clinic. Over the next 6 months participants will continue to receive standard of care (SOC).

    Behavioral: CHW-enabled CCL

  • No intervention
    Patients in a standard clinic that do not receive mHealth videos

    For 12 months participants will be followed as they receive SOC from their clinic.

Interventions

  • BehavioralCHW-enabled CCL

    The FHCs has access to the CHW-enabled CCL. With this intervention, participants will be screened for social determinants of health (SDoH) and be referred to care and social services that address any identified needs.

  • BehavioralMobile health (mHealth) diabetes self-management education and support (DSMES) videos

    Participants will receive 24 culturally tailored DSMES videos through text message.

06

What researchers measure

Primary outcomes

  1. Change in HbA1c levels

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Level of satisfaction with community-clinic linkage (CCL) and mHealth

    Participants are asked to rate satisfaction on a scale of 1 (not satisfied at all) to 10 (very satisfied).

    Time frame: Month 12

  2. Percentage of patients accepting Community Health Worker (CHW) support

    Time frame: Month 12

  3. Percentage of patients accepting mHealth

    Time frame: Month 12

  4. Percent completion of social service referrals

    Time frame: Month 6

  5. Percent mhealth videos watched

    Time frame: Month 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Brita.Roy@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Brita.Roy@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 28 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Aug 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartActual
Aug 14, 2026was Jan 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
NYU Langone Health is now Recruiting
Nov 13, 2026
Start date
Jan 2026→Aug 14, 2026 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    NYU Langone Health is now Recruiting
    Start date Jan 2026→Aug 14, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07296211
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Aug 14, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Brita Roy
Contact
Brita.Roy@nyulangone.org
347-377-3157
Julia Duch
Contact
Julia.Duch@nyulangone.org
201-424-3571
Nadia Islam, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion